CN108159017A - A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof - Google Patents
A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof Download PDFInfo
- Publication number
- CN108159017A CN108159017A CN201810219934.2A CN201810219934A CN108159017A CN 108159017 A CN108159017 A CN 108159017A CN 201810219934 A CN201810219934 A CN 201810219934A CN 108159017 A CN108159017 A CN 108159017A
- Authority
- CN
- China
- Prior art keywords
- parts
- lavo
- hydrochloride
- crospovidone
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Levofloxacin Hydrochloride Capsules and preparation method thereof, the component and part of the capsule includes：25 88 parts of lavo-ofloxacin hydrochloride, 26 48 parts of starch, 10 20 parts of dextrin, 48 parts of lactose, 6 12 parts of low-substituted hydroxypropyl cellulose, 34 parts of polyethylene glycol, 12 parts of surfactant, 12 parts of crospovidone, 24 parts of magnesium stearate, 45 parts of talcum powder, 12 parts of high melting-point wax.The present invention selects low-substituted hydroxypropyl cellulose, surfactant and crospovidone as disintegrant, magnesium stearate, talcum powder and high melting-point wax are as lubricant, complementary synergistic effect between them, it can make the particle fater disintegration in capsule, make drug-eluting, drug effect is brought into play rapidly, shortens the pain time of patient, the disintegrant and lubricant that the present invention combines are also fine with effect in tablets, can quickly make drug-eluting；In addition, manufacture craft is simple, cost is saved, is suitble to large-scale industrial production.
Description
Technical field
The present invention relates to a kind of capsule and preparation method thereof more particularly to a kind of Levofloxacin Hydrochloride Capsules and its preparations
Method.
Background technology
Lavo-ofloxacin hydrochloride is the levo form of Ofloxacin, and antibacterial activity is about twice of Ofloxacin, its master
Mechanism of action is wanted to inhibit bacteria DNA gyrases（Bacterial topoisomerase II）Activity, hinder bacterium DNA replication.Antimicrobial spectrum
Extensively, the characteristics of antibacterial action is strong.To most of enterobacteriaceae lactobacteriaceaes, such as escherichia coli, Klebsiella, Serratia, change
Shape Bacillus, Shigella, Salmonella, citrobacter, acinetobacter and pseudomonas aeruginosa, the bloodthirsty bar of influenza
The gram-negative bacterias such as bacterium, gonococcus have stronger antibacterial activity.To part methicillin-sensitivity staphylococcus, pneumonia streptococcus
The gram positive bacterias such as bacterium, micrococcus scarlatinae, hemolytic streptococcus and Legionella, mycoplasma, Chlamydia also have good antibacterial
Effect, but it is poor to anaerobic bacteria and enterococcal effect.
Suitable for caused by sensitive bacteria：1. urogenital infections, including pure, complexity urinary tract infections, bacterium
Property prostatitis, NEISSERIA GONORRHOEAE urethritis or cervicitis（Including person caused by producing enzyme strain）；2. respiratory tract infection is removed from office including sensitivity
Bronchial infection acute attack and pulmonary infection caused by blue negative bacillus；3. alimentary infection, by Shigella, Salmonella,
Caused by enterotoxigenic escherichia coli, aeromonas hydrophila, vibrio parahaemolytious etc.；4. typhoid fever；5. bone and the infection of joint；6. skin is soft
Tissue infection；7. the general infections such as septicemia.
Lavo-ofloxacin hydrochloride have many uses it is general, Principle of Pain unbearably in the case of, it is better that drug effect plays a role sooner,
This just needs the substance in Levofloxacin Hydrochloride Capsules that can quickly dissolve out, and then drug is made to play a role, but at present
Because the selection of disintegrant and lubricant is improper, the dissolution rate for making drug is less desirable.
Invention content
The object of the present invention is to provide a kind of Levofloxacin Hydrochloride Capsules and preparation method thereof, solve hydrochloric acid levofloxacin
Star pharmaceutical capsules dissolution rate is undesirable, and then prevents the problem of drug effect is from fast onset.
In order to achieve the above object, the present invention is achieved by the following technical solutions：
The present invention provides a kind of Levofloxacin Hydrochloride Capsules, and the component and part of the capsule includes：Hydrochloric acid levofloxacin
25-88 parts of star, 26-48 parts of starch, 10-20 parts of dextrin, 4-8 parts of lactose, 6-12 parts of low-substituted hydroxypropyl cellulose, polyethylene glycol 3-
4 parts, 1-2 parts of surfactant, 1-2 parts of crospovidone, 2-4 parts of magnesium stearate, 4-5 parts of talcum powder, 1-2 parts of high melting-point wax.
Preferably, the component and part of the capsule includes：25 parts of lavo-ofloxacin hydrochloride, 26 parts of starch, dextrin 10
Part, 4 parts of lactose, 6 parts of low-substituted hydroxypropyl cellulose, 3 parts of polyethylene glycol, 1 part of surfactant, 1 part of crospovidone, stearic acid
2 parts of magnesium, 4 parts of talcum powder, 1 part of high melting-point wax.
Preferably, the component and part of the capsule includes：88 parts of lavo-ofloxacin hydrochloride, 48 parts of starch, dextrin 20
Part, 8 parts of lactose, 12 parts of low-substituted hydroxypropyl cellulose, 4 parts of polyethylene glycol, 2 parts of surfactant, 2 parts of crospovidone, tristearin
Sour 4 parts of magnesium, 5 parts of talcum powder, 2 parts of high melting-point wax.
Preferably, the component and part of the capsule includes：56.5 parts of lavo-ofloxacin hydrochloride, 37 parts of starch, dextrin
15 parts, 6 parts of lactose, 9 parts of low-substituted hydroxypropyl cellulose, 3.5 parts of polyethylene glycol, 1.5 parts of surfactant, crospovidone 1.5
Part, 3 parts of magnesium stearate, 4.5 parts of talcum powder, 1.5 parts of high melting-point wax.
Preferably, surfactant is polyoxyethylene sorbitan monoleate and/or lauryl sodium sulfate.
The present invention also provides a kind of preparation methods of Levofloxacin Hydrochloride Capsules, specifically include following steps：
1）By starch, dextrin, lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, surfactant, crospovidone, tristearin
Sour magnesium, talcum powder and high melting-point wax sieving, and be sufficiently mixed, mixed material is obtained, mixed material is then crossed into 80 mesh
Sieve；
2) lavo-ofloxacin hydrochloride crushed 90 mesh sieve by；
3) is by step 1）In obtained mixed material and step 2）It is carried out after the lavo-ofloxacin hydrochloride drying obtained after middle sieving
It is sufficiently mixed；
4) lavo-ofloxacin hydrochloride material obtained in step 3) is filled capsule by by tire bagger, you can obtains product.
The present invention uses low-substituted hydroxypropyl cellulose, surfactant and crospovidone as disintegrant, general hydrophobic
Property or insoluble drugs to olighydria affinity, be not easy to be penetrated by water in hole, then can when adding in proper amount of surfactant
It is preferable to solve；Crospovidone is white powder, good fluidity, due to its high molecular weight and cross-linked structure, so insoluble
Yu Shui, but have it is extremely strong draw moist, water absorption can exceed that the 50% of itself weight, but remain to keep complete and do not dissolve, heap
Density is smaller（0.26g/ml）, therefore powder has larger specific surface area, is uniformly dispersed in capsule as disintegrant, in addition strong
Capillarity, promote network structure be disintegrated and generate calving disaggregation, effect is better than starch disintegrant；Low-substituted hydroxypropyl is fine
Tie up element be a kind of multiduty nonionic cellulose derivative, be mainly used as solid pharmaceutical preparation disintegration and adhesive, due to it
Powder has larger surface area and a porosity, thus can quick water swelling, while between its coarse structure and drug and particle
Have it is larger inlay, capsule endoparticle hardness can be significantly improved, while do not influence to be disintegrated, so as to accelerate the dissolution rate of drug, carried
High bioavilability；As lubricant, talcum powder is white to pale white crystals powder for magnesium stearate, talcum powder and high melting-point wax
End, good with white person, density is big, Adhesion Resistance and helps good fluidity, but adhesion and lubricity are poor, high melting-point wax typical concentrations
It is 3%~5%, lubricity is fine, and Adhesion Resistance is bad, helpless fluidity, and talcum powder and high melting-point wax can be fine as lubricant
Complementation, magnesium stearate is hydrophobe, and dosage, which crosses multipotency, to be influenced the disintegration time of tablet or generate sliver, using this hydrophobicity
During lubricant, can add in proper amount of surfactant such as lauryl sodium sulfate simultaneously can overcome.
Beneficial effects of the present invention：The present invention selects low-substituted hydroxypropyl cellulose, surfactant and crospovidone to make
For disintegrant, as lubricant, the complementary synergistic effect between them can make glue for magnesium stearate, talcum powder and high melting-point wax
Intracapsular particle fater disintegration, makes drug-eluting, and drug effect is brought into play rapidly, shortens the pain time of patient, of the present invention group
The disintegrant and lubricant of conjunction are also fine with effect in tablets, can quickly make drug-eluting；In addition, manufacture craft is simple,
Cost is saved, is suitble to large-scale industrial production.
Specific embodiment
With reference to embodiment, the specific embodiment of the present invention is further described.Following embodiment is only used for more
Add and clearly demonstrate technical scheme of the present invention, and be not intended to limit the protection scope of the present invention and limit the scope of the invention.
Embodiment 1
A kind of Levofloxacin Hydrochloride Capsules, the component and part of the capsule include：25 parts of lavo-ofloxacin hydrochloride, starch
26 parts, 10 parts of dextrin, 4 parts of lactose, 6 parts of low-substituted hydroxypropyl cellulose, 3 parts of polyethylene glycol, 1 part of polyoxyethylene sorbitan monoleate, the poly- dimension of crosslinking
1 part of ketone, 2 parts of magnesium stearate, 4 parts of talcum powder, 1 part of high melting-point wax.
A kind of preparation method of Levofloxacin Hydrochloride Capsules, specifically includes following steps：
1）By starch, dextrin, lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, polyoxyethylene sorbitan monoleate, crospovidone, tristearin
Sour magnesium, talcum powder and high melting-point wax sieving, and be sufficiently mixed, mixed material is obtained, mixed material is then crossed into 80 mesh
Sieve；
2) lavo-ofloxacin hydrochloride crushed 90 mesh sieve by；
3) is by step 1）In obtained mixed material and step 2）It is carried out after the lavo-ofloxacin hydrochloride drying obtained after middle sieving
It is sufficiently mixed；
4) lavo-ofloxacin hydrochloride material obtained in step 3) is filled capsule by by tire bagger, you can obtains product.
Application method：It oral 1 time on the one, 1~2 or is followed the doctor's advice every time according to the state of an illness.
Embodiment 2
A kind of Levofloxacin Hydrochloride Capsules, the component and part of the capsule include：88 parts of lavo-ofloxacin hydrochloride, starch
48 parts, 20 parts of dextrin, 8 parts of lactose, 12 parts of low-substituted hydroxypropyl cellulose, 4 parts of polyethylene glycol, 2 parts of lauryl sodium sulfate, crosslinking
2 parts of povidone, 4 parts of magnesium stearate, 5 parts of talcum powder, 2 parts of high melting-point wax.
A kind of preparation method of Levofloxacin Hydrochloride Capsules, specifically includes following steps：
1）By starch, dextrin, lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, surfactant, crospovidone, tristearin
Sour magnesium, talcum powder and high melting-point wax sieving, and be sufficiently mixed, mixed material is obtained, mixed material is then crossed into 80 mesh
Sieve；
2) lavo-ofloxacin hydrochloride crushed 90 mesh sieve by；
3) is by the step 1）In obtained mixed material and the step 2）The lavo-ofloxacin hydrochloride obtained after middle sieving is done
It is sufficiently mixed after dry；
4) lavo-ofloxacin hydrochloride material obtained in the step 3) is filled capsule by by tire bagger, you can obtains product.
Application method：It oral 1 time on the one, 1~2 or is followed the doctor's advice every time according to the state of an illness.
Embodiment 3
A kind of Levofloxacin Hydrochloride Capsules, the component and part of the capsule include：56.5 parts of lavo-ofloxacin hydrochloride forms sediment
37 parts of powder, 15 parts of dextrin, 6 parts of lactose, 9 parts of low-substituted hydroxypropyl cellulose, 3.5 parts of polyethylene glycol, 0.5 part of polyoxyethylene sorbitan monoleate, ten
1 part of sodium dialkyl sulfate, 1.5 parts of crospovidone, 3 parts of magnesium stearate, 4.5 parts of talcum powder, 1.5 parts of high melting-point wax.
A kind of preparation method of Levofloxacin Hydrochloride Capsules, specifically includes following steps：
1）By starch, dextrin, lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, surfactant, crospovidone, tristearin
Sour magnesium, talcum powder and high melting-point wax sieving, and be sufficiently mixed, mixed material is obtained, mixed material is then crossed into 80 mesh
Sieve；
2) lavo-ofloxacin hydrochloride crushed 90 mesh sieve by；
3) is by the step 1）In obtained mixed material and the step 2）The lavo-ofloxacin hydrochloride obtained after middle sieving is done
It is sufficiently mixed after dry；
4) lavo-ofloxacin hydrochloride material obtained in the step 3) is filled capsule by by tire bagger, you can obtains product.
Application method：It oral 1 time on the one, 1~2 or is followed the doctor's advice every time according to the state of an illness.
The Toxicity Analysis of the present invention：
1) clinical data
The present invention is used to treat bacterial prostatitis patient 186 and carries out clinical observation treatment, wherein age reckling 26
Year, the maximum 82 years old, average age 49 years old, course of disease 6-12 days.
2) efficacy assessment standard
It cures：Common disease is such as urinated discomfort, irritative symptoms of bladder occurs, and urethra scorching hot during such as frequent micturition, urination, early morning urethral orifice has
There is dysuric feeling etc. and all disappear in the secretion such as mucus, and therapeutic process does not have Nausea and vomiting, abdominal discomfort, abdomen
It rushes down, lose the appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache, fash, the lavo-ofloxacin hydrochlorides side effect symptom such as itching occur.
It improves：Common disease is such as urinated discomfort, irritative symptoms of bladder occurs, urethra scorching hot during such as frequent micturition, urination, early morning urethra
Mouth has a secretion such as mucus, occur it is dysuric feel etc. basic and disappear, therapeutic process do not have Nausea and vomiting, abdominal discomfort,
The lavo-ofloxacin hydrochlorides side effect symptom such as diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache, fash, itching goes out
It is existing.
In vain：Symptom is without being clearly better.
3) therapy
It takes orally 1 times a day, daily 1~2.
4) therapeutic effect
A kind of Levofloxacin Hydrochloride Capsules provided by the invention treat 186 patients, wherein there is 184 recoveries from illness, 2 good
Turn, 0 invalid；
Through statistical analysis, for cure rate up to 98.92%, total effective rate reaches 100%, has no any bad anti-over the course for the treatment of
Should, show Levofloxacin Hydrochloride Capsules drug safety of the invention.
Model case：
Case 1：In patient's summer, man, 31 years old, controlled micturition was uncomfortable, irritative symptoms of bladder occurs, urethra scorching hot during such as frequent micturition, urination
Etc. symptoms it is apparent, through other drugs treat 2 weeks effects it is bad, use the present invention Levofloxacin Hydrochloride Capsules treat 6 days effect
Fruit is clearly better, and fully recovers after being continuing with 6 days, during use without Nausea and vomiting, abdominal discomfort, diarrhea, loss of appetite,
The lavo-ofloxacin hydrochlorides side effect such as abdominal pain, abdominal distension, insomnia, dizziness, headache, fash, itching symptom occurs.
Case 2：Patient it is military certain, man, 56 years old, patient's early morning urethral orifice had the secretion such as mucus, dysuric sense occurs
The symptoms such as feel are apparent, bad through 2 weeks effects of other drugs treatment, treated 6 days using the Levofloxacin Hydrochloride Capsules of the present invention
Improvement with obvious effects is fully recovered after being continuing with 6 days, during use without Nausea and vomiting, abdominal discomfort, diarrhea, appetite not
It shakes, abdominal pain, abdominal distension, insomnia, dizziness, headache, fash, the lavo-ofloxacin hydrochlorides side effect symptom such as itching occur.
Case 3：Patient Zhang, man, 65 years old, controlled micturition was uncomfortable, irritative symptoms of bladder occurs, as urinated when frequent micturition, urination
Road is scorching hot, and early morning urethral orifice has the symptoms such as the secretion such as mucus, the dysuric feeling of appearance apparent, and 2 are treated through other drugs
Zhou Xiaoguo is bad, treats improvement with obvious effects in 6 days using the Levofloxacin Hydrochloride Capsules of the present invention, fullys recover from an illness after being continuing with 6 days
More, without Nausea and vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache, skin during use
The lavo-ofloxacin hydrochlorides side effect such as rash, itching symptom occurs.
Case 4：Patient Zhao, man, 79 years old, urethra scorching hot during controlled micturition, early morning urethral orifice had secretion such as mucus etc.
Symptom is apparent, bad through 2 weeks effects of other drugs treatment, and the Levofloxacin Hydrochloride Capsules of the present invention is used to treat 6 days effects
It is clearly better, fully recovers after being continuing with 6 days, without Nausea and vomiting, abdominal discomfort, diarrhea, loss of appetite, abdomen during use
Bitterly, the lavo-ofloxacin hydrochlorides side effect such as abdominal distension, insomnia, dizziness, headache, fash, itching symptom occurs.
The foregoing is only a preferred embodiment of the present invention, but protection scope of the present invention be not limited thereto,
Any one skilled in the art in the technical scope disclosed by the present invention, according to the technique and scheme of the present invention and its
Inventive concept is subject to equivalent substitution or change, should be covered by the protection scope of the present invention.
Claims (6)
1. a kind of Levofloxacin Hydrochloride Capsules, which is characterized in that the component and part of the capsule includes：The left oxygen fluorine of hydrochloric acid
Husky star 25-88 parts, 26-48 parts of starch, 10-20 parts of dextrin, 4-8 parts of lactose, 6-12 parts of low-substituted hydroxypropyl cellulose, polyethylene glycol
3-4 parts, 1-2 parts of surfactant, 1-2 parts of crospovidone, 2-4 parts of magnesium stearate, 4-5 parts of talcum powder, high melting-point wax 1-2
Part.
2. Levofloxacin Hydrochloride Capsules according to claim 1, it is characterised in that：The component and part of the capsule
Including：25 parts of lavo-ofloxacin hydrochloride, 26 parts of starch, 10 parts of dextrin, 4 parts of lactose, 6 parts of low-substituted hydroxypropyl cellulose, poly- second two
3 parts of alcohol, 1 part of surfactant, 1 part of crospovidone, 2 parts of magnesium stearate, 4 parts of talcum powder, 1 part of high melting-point wax.
3. Levofloxacin Hydrochloride Capsules according to claim 1, which is characterized in that the component and part of the capsule
Including：88 parts of lavo-ofloxacin hydrochloride, 48 parts of starch, 20 parts of dextrin, 8 parts of lactose, 12 parts of low-substituted hydroxypropyl cellulose, poly- second two
4 parts of alcohol, 2 parts of surfactant, 2 parts of crospovidone, 4 parts of magnesium stearate, 5 parts of talcum powder, 2 parts of high melting-point wax.
4. Levofloxacin Hydrochloride Capsules according to claim 1, which is characterized in that the component and part of the capsule
Including：56.5 parts of lavo-ofloxacin hydrochloride, 37 parts of starch, 15 parts of dextrin, 6 parts of lactose, 9 parts of low-substituted hydroxypropyl cellulose, poly- second
3.5 parts of glycol, 1.5 parts of surfactant, 1.5 parts of crospovidone, 3 parts of magnesium stearate, 4.5 parts of talcum powder, high melting-point wax 1.5
Part.
5. according to the Levofloxacin Hydrochloride Capsules described in any one of claim 1-4, which is characterized in that the surface-active
Agent is polyoxyethylene sorbitan monoleate and/or lauryl sodium sulfate.
It is 6. a kind of such as the preparation method of claim 5 Levofloxacin Hydrochloride Capsules, which is characterized in that specifically include following step
Suddenly：
1）By starch, dextrin, lactose, low-substituted hydroxypropyl cellulose, polyethylene glycol, surfactant, crospovidone, tristearin
Sour magnesium, talcum powder and high melting-point wax sieving, and be sufficiently mixed, mixed material is obtained, mixed material is then crossed into 80 mesh
Sieve；
2) lavo-ofloxacin hydrochloride crushed 90 mesh sieve by；
3) is by the step 1）In obtained mixed material and the step 2）The lavo-ofloxacin hydrochloride obtained after middle sieving is done
It is sufficiently mixed after dry；
4) lavo-ofloxacin hydrochloride material obtained in the step 3) is filled capsule by by tire bagger, you can obtains product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810219934.2A CN108159017A (en) | 2018-03-16 | 2018-03-16 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810219934.2A CN108159017A (en) | 2018-03-16 | 2018-03-16 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108159017A true CN108159017A (en) | 2018-06-15 |
Family
ID=62511248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810219934.2A Pending CN108159017A (en) | 2018-03-16 | 2018-03-16 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108159017A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567761A (en) * | 2018-07-25 | 2018-09-25 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
| CN108619157A (en) * | 2018-07-25 | 2018-10-09 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules |
| CN109793759A (en) * | 2019-03-06 | 2019-05-24 | 华中农业大学 | A kind of compound pollen cream ball and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606165A (en) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | Norfloxacin capsules and preparation method thereof |
| CN105687157A (en) * | 2014-11-29 | 2016-06-22 | 康普药业股份有限公司 | Levofloxacin hydrochloride capsule and preparation method thereof |
| CN107638404A (en) * | 2017-06-01 | 2018-01-30 | 合肥远志医药科技开发有限公司 | A kind of norfloxacin capsule and preparation method thereof |
-
2018
- 2018-03-16 CN CN201810219934.2A patent/CN108159017A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687157A (en) * | 2014-11-29 | 2016-06-22 | 康普药业股份有限公司 | Levofloxacin hydrochloride capsule and preparation method thereof |
| CN104606165A (en) * | 2015-02-04 | 2015-05-13 | 上海华源安徽仁济制药有限公司 | Norfloxacin capsules and preparation method thereof |
| CN107638404A (en) * | 2017-06-01 | 2018-01-30 | 合肥远志医药科技开发有限公司 | A kind of norfloxacin capsule and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567761A (en) * | 2018-07-25 | 2018-09-25 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof |
| CN108619157A (en) * | 2018-07-25 | 2018-10-09 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules |
| CN109793759A (en) * | 2019-03-06 | 2019-05-24 | 华中农业大学 | A kind of compound pollen cream ball and preparation method thereof |
| CN109793759B (en) * | 2019-03-06 | 2022-05-03 | 华中农业大学 | Compound pollen paste pill and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108159017A (en) | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof | |
| CN105770239A (en) | External health gel for treating gynecological inflammation | |
| CN102309553B (en) | Oral compound drug for treating oral ulcer | |
| CN103417562A (en) | Nifuratel-nysfungin vaginal soft capsule and preparation method thereof | |
| CN100364512C (en) | Houjiling prepn for treating throat diseases and its use | |
| CN104814964B (en) | A kind of pharmaceutical composition, the preparation method and applications of anti-stomach Helicobacter pylori | |
| CN101084912A (en) | Compound ambroxol hydrochloride sustained-release tablet and preparation method thereof | |
| CN116966206A (en) | Use of lactobacillus fermentum for the preparation of a product for the prevention and/or treatment of the colon of a laxative | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN110393768A (en) | A kind of combined traditional Chinese medicine dabbling drug of Gilt Uterus anti-inflammatory and its preparation method and application | |
| CN105832993B (en) | Composition with throat clearing function and preparation method and application thereof | |
| CN109172614A (en) | A kind of dedicated probiotic composition of women and its application | |
| CN105012912A (en) | Compound norfloxacin sustained release tablet and preparation method | |
| CN101612158A (en) | Compound ofloxacin injection of animals for treating postnatal infection and preparation method thereof | |
| JP5358219B2 (en) | Intestinal disease treatment | |
| CN101249141A (en) | Asiatic moonseed extract, preparations, preparing method and use thereof | |
| CN103356630A (en) | Medicinal composition containing pentoxifylline and prucalopride and medical application thereof | |
| CN104207130B (en) | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition | |
| CN112220740A (en) | Antibacterial and anti-inflammatory microgel for preventing or treating rhinitis and preparation method and application thereof | |
| CN105943718B (en) | Agilawood compound traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN102247387A (en) | Norfloxacin phenazopyridine tablets and preparation process method and use thereof | |
| CN103720749A (en) | Traditional Chinese medicinal preparation for treating elytritis | |
| CN100486613C (en) | Coryza-treating pharmaceutical compositions and its preparing process and uses | |
| CN113577090B (en) | Application of arctiin in preparation of prostatic hyperplasia medicine | |
| CN104958400A (en) | Oculentum for treating acute conjunctivitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180615 |